Generic placeholder image

Current Drug Safety

Editor-in-Chief

ISSN (Print): 1574-8863
ISSN (Online): 2212-3911

Topotecan in Second-Line Treatment of Small-Cell Lung Cancer – How it Works in Our Daily Clinical Practice?

Author(s): Ana Luisa Lourenco Moreira Faria, Emilio Macias Bravo, Marta Alexandra Silva Soares Rocha, Isabel Maria Azevedo Rocha, Ana Luisa Pequeno Coelho and Antonio Manuel Ferreira Araujo

Volume 5, Issue 2, 2010

Page: [114 - 117] Pages: 4

DOI: 10.2174/157488610790936123

Price: $65

Abstract

Lung cancer is one of the most commonly diagnosed malignancies and it causes more than 1 million deaths each year worldwide. Small-cell lung cancer (SCLC) accounts for about 15 to 20% of all lung cancers and it is an extremely aggressive cancer, having a response rate of 60-80% with the standard first-line chemotherapy (CT). Topotecan is a topoisomerase I inhibitor currently approved for relapsed SCLC. The authors reviewed the clinical files of SCLCs patients (pts) of a single institution, the Portuguese Institute of Oncology – Porto Centre, in a five year period. The end-points were to evaluate response rates (RR), time to progression (TTP), overall survival (OS) and toxicity profile of topotecan as a second-line treatment of SCLC. > From January of 2002 to December of 2006, 146 pts were diagnosed with SCLC, 32 were submitted to second-line treatment and 23 with topotecan. The RR was 17.4%, median TTP and median survival after topotecan were 2.8 months and 6.3 months, respectively, and median OS was 17.5 months. The incidence of grade 3 and 4 adverse events was 16.6 and 2.6%, respectively. Topotecan showed clinical activity in our unselected daily patients with relapsed SCLC, with acceptable toxicity, in accordance with the published literature.

Keywords: Small-cell lung cancer, topotecan, topoisomerase I inhibitor


Rights & Permissions Print Export Cite as
© 2024 Bentham Science Publishers | Privacy Policy